TheranosticTrials.org

Clinical Trial · NCT06636175

64Cu-LLP2A for Imaging Hematologic Malignancies

Overview

This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with negative imaging and suspected recurrence.

Sponsor

Washington University School of Medicine

Phase

Early Phase 1

Contacts

Farrokh Dehdashti, M.D. (PRINCIPAL_INVESTIGATOR)

Jennifer Frye, CNMT, CCRC (CONTACT)

fryej@wustl.edu

314-747-1604

Farrokh Dehdashti, M.D. (CONTACT)

dehdashtif@wustl.edu

314-362-1474

ClinicalTrials.gov

NCT06636175

Drug / Compound

LLP2A

Isotope(s):
Target(s):
  • Very Late Antigen-4 (integrin α4β1)
Ligand Class: Small Molecules
Chelator: CB-TE1A1P

Eligibility

Inclusion

  • Clinical or pathologically defined MM or lymphoma including both newly diagnosed, relapsed or refractory disease:
  • Multiple Myeloma defined in accordance with the International Myeloma Working Group criteria
  • Low-grade lymphoma, including the following subtypes: follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia

Exclusion

Exclusion criteria not yet provided.